Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · IEX Real-Time Price · USD
10.95
-0.28 (-2.49%)
Mar 30, 2023, 12:41 PM EDT - Market open
-2.49%
Market Cap 3.10B
Revenue (ttm) 329.23M
Net Income (ttm) -236.57M
Shares Out 282.72M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,025,482
Open 11.22
Previous Close 11.23
Day's Range 10.85 - 11.29
52-Week Range 5.91 - 13.84
Beta 0.82
Analysts Buy
Price Target 16.04 (+46.48%)
Earnings Date May 8, 2023

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate t... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 31, 2007
Employees 496
Stock Exchange NASDAQ
Ticker Symbol FOLD
Full Company Profile

Financial Performance

In 2022, FOLD's revenue was $329.23 million, an increase of 7.76% compared to the previous year's $305.51 million. Losses were -$236.57 million, -5.55% less than in 2021.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $16.04, which is an increase of 46.48% from the latest price.

Price Target
$16.04
(46.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe

Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).

2 days ago - Zacks Investment Research

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WUXI, China , March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic ...

2 days ago - PRNewsWire

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

Approved as a Long-Term Enzyme Replacement Therapy  in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease

3 days ago - GlobeNewsWire

Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates

Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.

3 weeks ago - Zacks Investment Research

Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

2022 Revenue Growth of 16% at CER to $329M

1 month ago - GlobeNewsWire

Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference i...

1 month ago - GlobeNewsWire

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve and ERT-Experienced Participants Out to Two Years

1 month ago - GlobeNewsWire

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023

PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:...

1 month ago - GlobeNewsWire

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the 1...

1 month ago - GlobeNewsWire

Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference

PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference...

1 month ago - GlobeNewsWire

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

Significant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022

2 months ago - GlobeNewsWire

Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Mo...

3 months ago - GlobeNewsWire

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data

3 months ago - GlobeNewsWire

Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference

PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New Y...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such investors are advise...

4 months ago - PRNewsWire

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

5 months ago - Zacks Investment Research

Amicus Therapeutics Provides EU Regulatory Update for AT-GAA

PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare ...

5 months ago - GlobeNewsWire

Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates

Year-to-Date 2022 Reported Revenue Growth of 8% (16% at CER)

5 months ago - GlobeNewsWire

U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability  to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date

5 months ago - GlobeNewsWire

Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:...

5 months ago - GlobeNewsWire

Amicus Therapeutics Announces Participation at World Muscle Society 2022

PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included at...

6 months ago - GlobeNewsWire

Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting

PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included ...

6 months ago - GlobeNewsWire